Pfizer plunges further into generics with Claris as new partner
This article was originally published in Scrip
Pfizer is plunging deeper into the generics space through an expanded alliance with Aurobindo Pharma and the acquisition of rights to 15 injectable products from Claris Lifesciences, both Indian companies.
You may also be interested in...
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.